Literature DB >> 22446734

Retrospective cohort study: a comparison of two different management strategies in patients with preterm premature rupture of membranes.

Azusa Shinjo1, Katsufumi Otsuki, Maki Sawada, Hajime Ota, Mayumi Tokunaka, Tomohiro Oba, Ryu Matsuoka, Takashi Okai.   

Abstract

PURPOSE: Perinatal outcomes were compared before and after changes in the treatment policy to improve the management for preterm PROM (pPROM).
METHODS: This is a retrospective analysis of 99 cases of pPROM diagnosed between 27 and 34 weeks of gestation, which were managed according to the following two different protocols. Group A (47 cases): tocolytic therapy was continued to prevent preterm delivery until clinical chorioamnionitis (CAM) was diagnosed between January 2000 and June 2004. Group B (52 cases): labor was induced or cesarean section performed when oligohydramnios was diagnosed and/or elevation elastase (EL) of amnion was detected by amniocentesis between July 2004 and July 2009. The outcomes of the cases in each group were compared with regard to the extension of pregnancy period, reasons for delivery, perinatal complications, stage of pathological CAM and funisitis (FUN), neonatal serum IgM concentration, mortality, and morbidity.
RESULTS: The incidences of pathological CAM and FUN were significantly lower in Group B than in Group A. The concentration of neonatal serum IgM was also significantly lower in Group B than in Group A.
CONCLUSIONS: The addition of oligohydramnios and elevation EL of amnion as indicative factors of intrauterine infection might lead to a reduction in the severity of fetal infection in cases of pPROM.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22446734     DOI: 10.1007/s00404-012-2271-0

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  1 in total

1.  Amniotic fluid rapid biomarkers are associated with intra-amniotic infection in preterm pregnancies regardless of the membrane status.

Authors:  T Myntti; L Rahkonen; M Tikkanen; A Pätäri-Sampo; J Paavonen; V Stefanovic
Journal:  J Perinatol       Date:  2016-04-07       Impact factor: 2.521

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.